Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride and Tropicamide, the active ingredients in Mydriasert, are mydriatic agents presented as an ophthalmic solution for ocular use. The combination rapidly dilates the pupil, aiding comprehensive eye examinations and facilitating intra‑ocular surgical procedures in adult patients.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets. Originating from the European Union, the product meets EU pharmacopeial standards throughout its lifecycle.

Mydriasert, a combination mydriatic ophthalmic solution, acts on the ocular pupil muscles to produce dilation.

- Eye examinations: provides sufficient pupil dilation for thorough retinal and optic nerve assessment. - Intra‑ocular procedures: facilitates surgical access by maintaining a wide pupil during cataract or laser surgery. - Diagnostic imaging: enables high‑quality fundus photography and optical coherence tomography. - Pre‑operative preparation: dilates pupils before cataract extraction to improve surgeon visibility.

Mydriasert may cause ocular and systemic reactions following administration.

Common Side Effects: - Transient ocular discomfort or stinging. - Blurred vision lasting several hours. - Photophobia due to enlarged pupil. - Mild conjunctival redness.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Severe allergic reaction (e.g., edema, rash, anaphylaxis). - Systemic hypertension or tachycardia. - Persistent intra‑ocular pressure elevation. - Ocular ischemia or corneal edema.

Use of Mydriasert requires careful assessment and monitoring.

- Assess intra‑ocular pressure: measure baseline pressure before instillation. - Narrow‑angle glaucoma: avoid or use only under specialist supervision. - Hypersensitivity: discontinue if allergic signs appear. - Cardiovascular disease: monitor for systemic blood pressure changes. - Concomitant mydriatics: limit combined use to prevent excessive dilation. - Store at room temperature: keep in original container, protect from light and moisture.

Mydriasert can interact with systemic and ocular agents.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis with phenylephrine. - Tricyclic antidepressants or sympathomimetics: may potentiate systemic vasoconstriction. - Anticholinergic drugs: increased ocular anticholinergic effect with tropicamide.

Moderate Interactions (Monitor Closely): - Beta‑blockers or antihypertensives: possible attenuation of systemic blood pressure rise. - Other mydriatic agents: risk of excessive pupil dilation. - Topical ocular steroids: may mask signs of increased intra‑ocular pressure.